Revisão Acesso aberto Revisado por pares

Botulinum toxin type A in the treatment of Myofascial Pain Syndrome: A Systematic Review

2021; Medical Association of São Paulo; Linguagem: Inglês

10.5327/1516-3180.263

ISSN

1806-9460

Autores

Gabriel Cerqueira Santos, Caio de Almeida Lellis, Bruno Coelho Duarte Oliveira, Letícia Romeira Belchior, Caíque Seabra Garcia de Menezes Figueiredo, Ledismar José da Silva,

Tópico(s)

Linguistics and Language Studies

Resumo

Introduction: Myofascial pain syndrome (MPS) is a regional painful condition characterized by the presence of trigger points in the affected muscles, and botulinum toxin type A (BoNT-A) is a possible therapeutic option. Objectives: To evaluate the safety and efficacy of botulinum toxin in the management of MSD. Design and setting: A systematic review conducted at the Pontifical Catholic University of Goiás. Methodology: A systematic review was conducted in the PubMed, IBECS and VHL databases: “(Myofascial Pain Syndromes OR Myofascial Trigger Point Pain) AND Botulinum toxin”. Randomized studies, clinical trials and case reports published in the last 10 years were selected. Results: Two randomized trials concluded that application of BoNT-A, regard less of the application site, did not show significant improvement in pain intensity compared to the control group. Also, another multicenter, random ized trial reported that application of ToNB-A to the masseter muscles did not result in improvement of SDM within three months of application. Finally, a clinical trial reported improvement in visual numeric scores of myofascial pain in the scapular girdle in subjects who received a second dose (P = 0.019). Conclusion: BoNT-A was not effective in improving SDM at any site of ap plication and in any dosage studied, except in a single study, therefore insuf ficient to state whether subsequent doses have better results.

Referência(s)
Altmetric
PlumX